<DOC>
	<DOCNO>NCT01461460</DOCNO>
	<brief_summary>The purpose study assess effect oral TR-701 free acid ( FA ) versus placebo QTcF .</brief_summary>
	<brief_title>A Thorough QT Study TR-701free Acid ( FA ) Healthy Subjects</brief_title>
	<detailed_description>To assess effect single therapeutic ( 200 mg ) supratherapeutic oral TR-701 free acid ( FA ) versus placebo QT interval correct heart rate use Fridericia 's formula ( QTcF ) healthy subject .</detailed_description>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Torezolid</mesh_term>
	<mesh_term>Torezolid phosphate</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Male female subject 18 45 year age , inclusive . Healthy male female clinically significant abnormality . Body mass index ≥18.0 kg/m2 ≤30.0 kg/m2 Sustained supine systolic blood pressure &gt; 140 &lt; 100 mmHg diastolic blood pressure &gt; 90 &lt; 60 mmHg Screening Day 1 Visit . Abnormal ECG Screening Day 1 Visits indicate second thirddegree atrioventricular block , QRS &gt; 110 msec , QTcF &gt; 450 msec male &gt; 470 msec female , PR interval &gt; 200 msec , rhythm sinus rhythm interpret Investigator clinically significant History unexplained infection current sign infection History risk factor Torsades de Pointes , include unexplained syncope , know Long QT Syndrome , heart failure , myocardial infarction , angina , clinically significant abnormal laboratory assessment include hypokalemia , hypercalcemia , hypomagnesemia , family history Long QT Syndrome Brugada Syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>volunteer</keyword>
</DOC>